Results 171 to 180 of about 8,578 (238)

Development of antibody-drug conjugates in gastric cancer: an overview of clinical trials from 2005 to 2025. [PDF]

Int J Surg
Duan R.
europepmc   +1 more source

An Integrated NMR Approach for Evaluating Linker-Payload Conjugation with Monoclonal Antibodies. [PDF]

Bioconjug Chem
Ghini V, Siciliano S, Querci L, Angiolini L, Truglio GI, Cini E, Piccioli M, Petricci E, Turano P.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Arming antibodies: prospects and challenges for immunoconjugates

Nature Biotechnology, 2005
Immunoconjugates--monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs (ineffective when administered systemically alone)--are becoming a significant component of anticancer treatments. By combining the exquisite targeting specificity of mAbs with the enhanced tumor-killing power of toxic effector ...
Anna M Wu, Peter D Senter, Wu Anna M
exaly   +4 more sources

Designing immunoconjugates for cancer therapy

Expert Opinion on Biological Therapy, 2012
Antibody-drug conjugates (ADCs), as well as antibody conjugates of protein toxins (immunotoxins) and cytokines (immunocytokines), are showing clinical efficacy, with manageable toxicities, in cancer treatment.The utility of an ADC is governed by the antibody and the target, as well as by the drug-linker component of the conjugate. The conjugation site,
S. Govindan, D. Goldenberg
semanticscholar   +3 more sources

Are immunoconjugates approaching “standard of care” in AML?

Best Practice and Research in Clinical Haematology, 2013
It seems clear that immunoconjugates, the combinations of antibodies with toxins, will play a role in therapy of acute myeloid leukemia (AML). It is also clear that sole emphasis on an average trial result is misplaced in AML, as the example of gentuzumab ozogamicin illustrates.
Elihu H Estey
exaly   +3 more sources

Immunoconjugates of Carbon Nanostructures

, 2006
For the first time, carbon nanostructures have been designed and synthesized to form immunoconjugates with monoclonal antibodies (mAb) for use in cell-targeted cancer diagnosis and therapy. The immunoconjugates are derived from various nanoscale carbon-based building blocks, specifically fullerenes (C60 ), gadofullerenes (M C60) and ultra-short carbon ...
Ashcroft, Jared Mark
openaire   +2 more sources

Immunoconjugates: Current Status and Future Potential

Journal of Drug Targeting, 2002
Whilst the concepts involved in immunoconjugates go back two centuries to the ideas of Ehrlich; it was only in the early 1980s that biotechnology gave us the tools to make pure immunoconjugates, in quantities sufficient for clinical studies [Garnett, M.C. (2002) "Targeted drug conjugates: principles and progress".
exaly   +3 more sources

Understanding Structural/Functional Properties of Immunoconjugates for Cancer Therapy by Computational Approaches

Journal of Biomolecular Structure and Dynamics, 2008
: Monoclonal antibodies coupled to highly toxic molecules (immunoconjugates) are currently being developed for cancer therapy. We have used an in silico procedure for evaluating some physicochemical properties of two tumor-targeting anti-HER2 ...
Caterina Arcangeli, Patrizia Galeffi, Vittorio Rosato   +2 more
exaly   +2 more sources